AEON Biopharma

Moat components assessed: 1) Intangibles/Regulatory positioning: moderate potential if FDA confers biosimilar status and allows indication extrapolation across Botox’s therapeutic label. This could create label parity and lower operational friction versus incumbent alternatives, but the outcome is uncertain.

Score: 35/100. 2) Switching costs: potential if ABP‑450 achieves 1:1 unit use, same vial size, dosing and dilution as Botox; today switching costs favor Botox’s entrenched label and workflows. Score: 30/100. 3) Network effects: none; adoption depends on physician behavior, payers and reimbursement rather than user‑driven network dynamics.

Score: 5/100. 4) Cost advantage: upside from AEON’s license/supply terms with Daewoong that include no milestones or royalties and agreed transfer pricing, which could support competitive net pricing, though scale and payer dynamics will drive realization.

Score: 40/100. 5) Efficient scale: none yet; the market is large but dominated by a powerful incumbent with established distribution.

Score: 10/100. Weighted view: even if biosimilarity is achieved, Botox’s brand and embedded practice patterns limit durable advantage near term; moat strength remains prospective and contingent on regulatory success and execution.